Authors: the UC Davis Post-COVID-19 clinic CORONAVIRUS February 11, 2022 Known to health experts as post-acute sequelae SARS-CoV-2 infection (PASC), it is more commonly known as long-haul COVID or long COVID. The Centers for Disease Control describes post-COVID conditions as ongoing or new symptoms occurring a month or more after a COVID-19 infection. It is estimated that between 10% to 30% of […]
Authors: Alex Berenson New figures from Britain raise bright red flags about the direction of Covid in wealthy countries that used mRNA and DNA shots to attempt to defeat the coronavirus last year. Hospitalizations and deaths remain stubbornly high and overwhelmingly occur in vaccinated people. In February, 90 percent of the 1,000 Britons who died […]
AuthorsAlexander Supadya,c,d and Robert Zeiserb Lancet Respir Med. 2022 Feb 3doi: 10.1016/S2213-2600(22)00021-2 [Epub ahead of print]PMCID: PMC8813061PMID: 35123659 Mortality is high among patients with severe COVID-19 who require invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).1, 2 Therefore, further specific treatment options for these patients are urgently needed. Early in the COVID-19 pandemic, Janus kinase (JAK) inhibitors were identified as potential therapeutic agents […]
Authors: Jonathan A. Stefely,Bianca B. Christensen,Tasos Gogakos,Jensyn K. Cone Sullivan … See all authors First published: 24 August 2020 https://doi.org/10.1002/ajh.25979 Abstract Coagulopathy causes morbidity and mortality in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Yet, the mechanisms are unclear and biomarkers are limited. Early in the pandemic, we observed markedly elevated […]
Authors: Patrick J Lindsay, a Rachel Rosovsky, b Edward A Bittner, c and Marvin G. Chang c ABSTRACT Introduction COVID-19-associated coagulopathy (CAC) is a well-recognized hematologic complication among patients with severe COVID-19 disease, where macro- and micro-thrombosis can lead to multiorgan injury and failure. Major societal guidelines that have published on the management of CAC are based on consensus of expert opinion, with […]
Ali Tabatabai 1, Joseph Rabin 2, Jay Menaker 2, Ronson Madathil 3, Samuel Galvagno 4, Ashley Menne 5, Jonathan H Chow 4, Alison Grazioli 6, Daniel Herr 1, Kenichi Tanaka 4, Thomas Scalea 2, Michael Mazzeffi 4Affiliations expand PMID: 32539272 PMCID: PMC7242090 DOI: 10.1213/XAA.0000000000001236 Abstract Critically ill patients with coronavirus disease 2019 (COVID-19) have been observed to be hypercoagulable, but the mechanisms for this remain poorly described. Factor VIII is a procoagulant factor that increases during inflammation and is cleaved by activated […]
Authors: Athanasios Kousathanas, Erola Pairo-Castineira, J. Kenneth BaillieArticle Published: 07 March 2022 nature articles article We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply. Abstract Critical Covid-19 is […]
Authors: Waldemar Kanczkowski. Katja Evert. Marlena Stadtmüller, Martina Haberecker, Laura Laks, Lan-Sun Chen, et al. Published:November 18, 2021DOI:https://doi.org/10.1016/S2213-8587(21)00291-6PlumX Metrics COVID-19 develops due to infection with SARS-CoV-2, which particularly in elderly with certain comorbidities (eg, metabolic syndrome)1 can cause severe pneumonia and acute respiratory distress syndrome. Some patients with severe COVID-19 will develop a life-threatening sepsis with […]
For hospitalized patients already taking other proven COVID-19 drugs, pill further reduces chance of death Authors: KAI KUPFERSCHMIDT 3 MAR 2022 1:20 PM Baricitinib, an oral drug that dampens an overactive immune system and is commonly used by people with rheumatoid arthritis, reduced hospitalized COVID-19 patients’ risk of dying by 13%, investigators of the world’s […]
